Skip to main content

Ibex Medical, UPMC Partner to Validate Prostate Cancer Dx System

NEW YORK (360Dx) — Israeli diagnostics firm Ibex Medical Analytics said today that it has partnered with the University of Pittsburgh Medical Center (UPMC) to validate its artificial intelligence-based prostate cancer diagnostic system.

Liron Pantanowitz, a professor of pathology and biomedical informatics and vice chairman of pathology informatics at UPMC Shadyside, will also collaborate on the partnership.

Under the terms of the deal, the partners will use Ibex's Second Read (SR) system — which uses AI and machine learning to identify various cell types and features in images of prostate core needle biopsies — on samples collected by UPMC.

Additional terms were not disclosed.

"This collaboration will enable us to further demonstrate our system's validity and is a significant milestone in our journey to make pathology labs more accurate and efficient," Ibex CEO Joseph Mossel said in a statement.

Earlier this year, Ibex announced that it had deployed the SR system in a clinical setting at Maccabi Healthcare Services' pathology institute.